Drugs / Iparomlimab and Tuvonralimab
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07392346 | Dec 2025 → Nov 2027 expected | gastric adenocarcinoma | Dai, Guanghai | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Iparomlimab and Tuvonralimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07392346 ↗ |
| Known as | Iparomlimab and Tuvonralimab Injection | “Iparomlimab and Tuvonralimab Injection (a novel bispecific antibody)” NCT07392346 ↗ |
| Modality | Monoclonal antibody | “Iparomlimab and Tuvonralimab Injection (a novel bispecific antibody)” NCT07392346 ↗ |
| Route | Intravenous | “5.0 mg/kg, Day 1, q3W, iv” NCT07392346 ↗ |